These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 32299813)

  • 1. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
    Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
    Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
    Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
    Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.
    Sveen A; Løes IM; Alagaratnam S; Nilsen G; Høland M; Lingjærde OC; Sorbye H; Berg KC; Horn A; Angelsen JH; Knappskog S; Lønning PE; Lothe RA
    PLoS Genet; 2016 Jul; 12(7):e1006225. PubMed ID: 27472274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
    Cioce M; Fumagalli MR; Donzelli S; Goeman F; Canu V; Rutigliano D; Orlandi G; Sacconi A; Pulito C; Palcau AC; Fanciulli M; Morrone A; Diodoro MG; Caricato M; Crescenzi A; Verri M; Fazio VM; Zapperi S; Levrero M; Strano S; Grazi GL; La Porta C; Blandino G
    J Exp Clin Cancer Res; 2023 Jul; 42(1):170. PubMed ID: 37460938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.
    Graziano F; Ruzzo A; Giacomini E; Ricciardi T; Aprile G; Loupakis F; Lorenzini P; Ongaro E; Zoratto F; Catalano V; Sarti D; Rulli E; Cremolini C; De Nictolis M; De Maglio G; Falcone A; Fiorentini G; Magnani M
    Pharmacogenomics J; 2017 Jun; 17(3):258-264. PubMed ID: 26927284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
    Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
    Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
    Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA
    Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity.
    Brown KM; Xue A; Julovi SM; Gill AJ; Pavlakis N; Samra JS; Smith RC; Hugh TJ
    J Surg Res; 2018 Jul; 227():158-167. PubMed ID: 29804848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
    Das S; Allen A; Berlin J
    Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.
    Kryeziu K; Moosavi SH; Bergsland CH; Guren MG; Eide PW; Totland MZ; Lassen K; Abildgaard A; Nesbakken A; Sveen A; Lothe RA
    J Transl Med; 2021 Sep; 19(1):384. PubMed ID: 34496878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.
    Lu M; Zessin AS; Glover W; Hsu DS
    PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
    Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
    Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.